Basal cell carcinoma treated with MTDQ and irradiation.
Patients with basal cell carcinoma of the skin were treated with combined MTDQ (6,6'-methylene-bis-(2,2,4-trimethyl-1,2-dihydroquinoline)) administration and irradiation. Significantly better results were obtained with a skin exposure of 2 000 R combined with MTDQ than with the same dose alone. The results were comparable to those obtained with an exposure of 4 000 R. MTDQ administration induced decrease of tissular malonaldehyde concentration and suggested the peroxide-decomposing action of the radiation sensitizer.
D000328:Adult; D002280:Basal Cell Carcinoma / Q000378:metabolism / Q000532:radiotherapy*; D006801:Humans; D008315:Malondialdehyde / Q000378:metabolism; D011292:Premedication; D011804:Quinolines / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000378:metabolism; D011879:Radiotherapy Dosage; D012867:Skin / Q000378:metabolism; D012878:Skin Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D013607:Tablets
D011804:Quinolines; D011838:Radiation-Sensitizing Agents; D013607:Tablets; C011923:6,6'-methylene bis(2,2,4-trimethyl-1,2-dihydroquinoline); D008315:Malondialdehyde